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Basal cell carcinoma (BCC) is a very common malignant skin
tumor that rarely metastatizes, but is often locally aggressive.
Several factors, like large size (more than 3 cm), exposure to
ultraviolet rays, histological variants, level of infiltration and
perineural or perivascular invasion,are associated with a more
aggressive clinical course.These morphological features seem
to be more determinant in mideface localized BCC, which fre-
quently show a significantly higher recurrence rate. An
immunohistochemical profile, characterized by reactivity of
tumor cells for p53, Ki67 and alpha-SMA has been associat-
ed with a more aggressive behaviour in large BCCs.The aim of
this study was to verify if also little (<3 cm) basal cell carcino-
mas can express immunohistochemical markers typical for an
aggressive behaviour.
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B
asal cell carcinoma (BCC) is a very common
malignant skin tumor that rarely metasta-
tizes, even if is often locally aggressive.
Several factors, like large size (more than 3 cm),
face localization,exposure to ultraviolet rays,histo-
logical variants, infiltration level and perineural or
perivascular invasion, are associated with a more
aggressive clinical course. In particular, the inci-
dence of metastasis and/or death correlates with
tumors greater than 3 cm in diameter in which set-
ting patients are said to have 1-2 % risk of metas-
tases that increases to 20-25% in lesions greater
than 5 cm and to 50% in lesions greater than 10
cm in diameter (Snow et al., 1994). Histologically
morpheiform,keratotic types and infiltrative growth
of BCC are also considered features of the most
aggressive course (Crowson, 2006). This can be
explained by the fact that both the superficial and
nodular variants of BCC are surrounded by a con-
tinuous basement membrane  zone comprising col-
lagens type IV and V admixed with laminin, while
the aggressive growth variants (i.e. morpheiform,
metatypical, and infiltrative growth subtypes) man-
ifest the absence of basement membrane (Barsky et
al., 1987).
The molecular markers which characterize
aggressive BCC include: increased expression of
stromolysin (MMP-3) and collagenase-1 (MMP-1)
(Cribier et al., 2001), decreased expression of syn-
decan-1 proteoglycan (Bayer-Garner et al., 2000)
and of anti-apoptotic protein bcl-2 (Ramdial et al.,
2000; Staibano et al., 2001).
C-ras ,c-fos (Urabe et al.,1994;Van der Schroeff
et al., 1990) and p53 tumor supressor gene muta-
tions (Auepemikiate et al., 2002) are indicative of
an aggressive course.
Focusing upon bcl-2 and p53 expression in BCC,
there have been numerous studies documenting the
utility of bcl-2 as a marker of favourable clinical
behaviour while p53 expression may be a feature of
a more aggressive outcome (Ramdial et al., 2000;
Staibano et al., 2001; Bozdogan et al., 2002).
LETTER  TO THE EDITOR
                 An increased expression of cytoskeletal microfila-
ments like α–smooth muscle actin,frequently found
in invasive BCC subtypes (Jones JCR et al., 1989),
may explain an enhanced tumor mobility and deep
tissue invasion through the stroma. (Cristian et al.,
2001; Law et al., 2003). The aim of this prelimi-
nary study was  to verify if also little (<3 cm) basal
cell carcinomas may express aggressive immunohis-
tochemical markers like p53, Ki67 and alpha-
SMA.We used 31 excisional BCCs with tumor size
less than 2 cm (ranging from 2 up to 20 mm) and
with different skin localization (19 in the face, 6 in
the trunk and 6 in the body extremities). All cases
were immunostained for p53, BCL2, Ki67 and
alpha-smooth muscle actin (α-SMA) (Table 1).
Immunoreactivity was evaluated by a semiquantita-
tive score from 0 to 4, and interpreted by a two
board-certified dermatopathologists (L.P. and
C.M).
Our data show that p53 (75%),Bcl2 (50%) and
Ki67 (63%) positivity was generally diffuse in the
majority of cases.On the contrary,cytoplasmatic α-
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Table 1. Clinical (age, sex, location, size), histological (histotype, depth infiltration in millimetre, ulceration, essudation and level of
infiltration according anatomical skin layers URD upper reticular dermis; DRD deep reticular dermis ) and immunohistochemical data
of 31 cases of BBC; essudation Mild=+; Moderate=++;Severe=+++; immunohistochemical score: 0= 0-6%; 1= 6-25%; 2= 25-50%;
3=51-75%;4=76-100%.
Age Sex Location Hystotype Max.Dim Depth Ulc Ess Inf p53 Bcl-2 Ki67 AML
1 61 M Extr Keratotic 10x8 1 No  +++ URD +++ + + -
2 61 M Face Adenoid 10x9 4 No + URD +++ - - -
3 64 M Extr Sup mult 11x13 0.8 No + DRD + - - -
4 73 M Face Nodular 10x8 2 Yes + DRD +++ + ++ +++
5 84 M Face Nodular 9x12  2 Yes + DRD - - - -
6 84 M Face Adenoid 5 0.8 No + URD +++ - - -
7 84 M Extr Nodular 13x10 3 No + DRD +++ + + -
8 52 F Face Nodular 4 0.8 No + URD + + + -
9 76 F Face Adenoid 10x4 4 No + DRD +++ - ++ -
10 77 F Face Morph 8x6 1 Yes +++ DRD +++ - - -
11 86 M Face Morph 8 1 Yes + DRD +++ - + +
12 63 F Face Adenoid 4 1 No + URD ++ + + +
13 76 F Face Nodular 7 1.5 No + DRD +++ + ++ -
14 84 M Face Nodular 11 4 Yes +++ DRD + - - +
15 63 F Face Keratotic 10x6 1.8 No ++ DRD - + ++ -
16 68 F Trunk Sup mult 10x6 0.7 No ++ URD + + - -
17 67 M Face Sup mult 12x6 0.4 No + URD + - + -
18 67 M Extr Sup mult 4x3 0.3 No + URD + +++ + -
19 32 F Extr Sup mult 1x3 0.4 No + URD + + + -
20 45 M Trunk Nodular 7x5 2 Yes +++ URD + + + -
21 62 M Trunk Sup mult 11x7 0.9 No ++ URD - ++ - ++
22 65 M Trunk Adenoid 7x6 1.5 No + URD +++ + + -
23 72 M Trunk Nodular 12x6 1 No + URD +++ - + +
24 86 F Face Keratotic 20x11 3.1 No ++ DRD + + + -
25 85 M Face Nodular 0.5 1.3 No ++ DRD ++ + + -
26 74 F Extr Nodular 4x4 0.9 No + URD - - + -
27 71 M Face Nodular 6x12 1.7 No + DRD - - + -
28 64 F Trunk Sup mult 1.3x1.5 0.4 No ++ URD +++ - - -
29 78 F Face Nodular 4x3 1.5 No ++ DRD ++ + - +++
30 80 M Face Keratotic 4x4 1.6 Yes + DRD - - + +++
Table 2. Comparison of our 8 α α-SMA positive cases with negative cases.
Location Histotype Local aggressiveness Immunohistochemistry
Face Keratotic Morpheiform Depht of invasion  Ulceration Infiltration  P53 Bcl-2 Ki67
Mean value(mm) of the dermis
8 α-SMA 75% 12% 12% 1.6 50% 63% 75% 50% 63%
positive cases
23 α-SMA 56% 13% 4% 1.4 13% 48% 78% 43% 65%
negative casesSMA expression was present only in 8 out of 31
cases (25,8%). All these 8 α-SMA positive BCCs,
prevalently found in the mideface (6 out of 8),were
characterized by an initial invasion beyond the der-
mis. Among these 6 face-localized α-SMA positive
BCCs,1 showed a sclerosing aggressive histotype,1
a keratotic type and 4 a nodular histotype.
These 8 little α-SMA-positive BCCs,compared to
the others 23 α-SMA negative samples, all showed
a major aggressiveness features: facial location,
ulceration, morpheiform histotype and deeper infil-
tration into the dermis (Table 2). In particular,
75% of these α-SMA positive BCCs were localized
in the midface; 24% presented with an aggressive
histotype (keratotic and morpheiform); 50%
showed ulceration; 63% tended to infiltrate the
dermis deeply, with a mean depth of invasion of 1,6
mm (Table 2).
Given the absence of a specific difference between
α-SMA positive cases and α-SMA negative cases
in the expression of aggressive immunohistochemi-
cal markers, except for a light reduction of bcl-2 in
the α-SMA positive group (Table 2), we focused
our  attention not only on the single marker but on
the several possible immunohistochemical profiles
that we could obtain (Tables 1 and 2).By the analy-
sis of the data, we selected the combination that
could better define an aggressive behaviour even for
little BCC: α-SMA, p53, Ki67 positivity and  bcl-2
negativity.We considered p53 and ki67 markers of
proliferation and cell-cycle alteration, combined
with a loss of apoptotic activity expressed by Bcl-2
negativity, quite characteristic of aggressiveness;
moreover α-SMA positivity probably reflects inva-
sive potential and acquired mobility by neoplastic
cells.
This immunohistochemical profile (α-SMA, p53,
Ki67 positivity and  bcl-2 negativity) in our cases of
BCC is present in two of them; one is a mor-
pheiform BCC, that is an aggressive variant, while
the other one is a nodular subtype (less aggressive).
Therefore, our preliminary data suggest that only
α-SMA positivity should be considered as an early
diagnostic marker of potential aggressiveness in lit-
tle BCC: all  α-SMA positive little BCC in fact
showed clinical and histological features of aggres-
siveness. Invasive potential is probably acquired by
some BCCs not only when they  reach large size,but
it is probably present also when they have still little
size,and can be revealed by α-SMA positivity in the
neoplastic cells.
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